Opendata, web and dolomites

PharmaLedger SIGNED

PharmaLedger

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PharmaLedger project word cloud

Explore the words cloud of the PharmaLedger project. It provides you a very rough idea of what is the project "PharmaLedger" about.

machine    trials    pharmaledger    security    sustainability    framework    compliance    governance    marketplaces    recruitment    integrity    platform    pharmaceutical    innovation    interoperability    validation    digitization    serve    decentralized    patient    efficiency    records    blockchain    providers    actionable    counterfeit    entire    adoption    connectivity    enabled    combating    methodology    learning    standards    source    industry    limited    chain    brings    efficient    regulation    analytics    solutions    documented    trusted    truth    smes    supply    specializing    successful    patients    11    intelligence    manufacturers    business    health    designed    single    benefit    tracking    medical    ecosystem    submission    create    technologies    big    stakeholders    privacy    institutes    prioritized    pharmacoeconomic    service    healthcare    28    accelerating    reference    supplies    data    extant    electronic    leveraging    medicines    ensured    evolutionary    innovative    clinical    universities    companies   

Project "PharmaLedger" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD POLITECNICA DE MADRID 

Organization address
address: CALLE RAMIRO DE MAEZTU 7 EDIFICIO RECTORADO
city: MADRID
postcode: 28040
website: www.upm.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 20˙920˙901 €
 EC max contribution 8˙290˙693 € (40%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-15-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD POLITECNICA DE MADRID ES (MADRID) coordinator 873˙750.00
2    ROMSOFT SRL RO (IASI) participant 1˙157˙500.00
3    TECHNOVATIVE SOLUTIONS LTD UK (MANCHESTER) participant 910˙625.00
4    ARTEEVO TECHNOLOGIES LTD IL (TEL AVIV) participant 906˙250.00
5    PDM E FC PROJECTO DESENVOLVIMENTO MANUTENCAO FORMACAO E CONSULTADORIALDA PT (LISBOA) participant 648˙125.00
6    ONORACH LTD UK (DUNDEE) participant 511˙568.00
7    EKON MODELING SOFWARE SYSTEMS LTD*EKON IL (Modi'in-Maccabim-Re'ut) participant 456˙250.00
8    NATIONAL RESEARCH AND DEVELOPMENT INSTITUTE FOR CRYOGENICS AND ISOTOPIC TECHNOLOGIES ICSI RM VALCEA RO (RAMNICU VALCEA) participant 370˙000.00
9    IMPRENSA NACIONAL - CASA DA MOEDA, S. A. PT (LISBOA) participant 365˙625.00
10    HOSPITAL DO ESPIRITO SANTO DE EVORA EPE PT (EVORA) participant 351˙250.00
11    OSPEDALE PEDIATRICO BAMBINO GESU IT (ROMA) participant 347˙500.00
12    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 338˙500.00
13    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 307˙500.00
14    ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS EL (THERMI THESSALONIKI) participant 282˙500.00
15    DIMOKRITIO PANEPISTIMIO THRAKIS EL (KOMOTINI) participant 216˙250.00
16    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) participant 143˙750.00
17    EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE BE (BRUSSELS) participant 103˙750.00
18    ABBVIE INC US (NORTH CHICAGO IL) participant 0.00
19    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
20    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
21    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
22    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
23    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
24    MERCK SHARP & DOHME CORP US (WHITEHOUSE STATION NJ) participant 0.00
25    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
26    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
27    PFIZER LIMITED UK (SANDWICH) participant 0.00
28    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the project is to provide a widely trusted platform that will support the design and adoption of blockchain-enabled healthcare solutions while accelerating delivery of innovation that will benefit the entire ecosystem, from manufacturers to patients. PharmaLedger will serve as a single source of truth for the healthcare ecosystem and will be designed for efficient decentralized governance, wide adoption by the stakeholders of the ecosystem, compliance with extant and emerging standards and regulation, and end-to-end connectivity and interoperability. Sustainability of the platform will be ensured by leveraging existing, successful blockchain technologies; open source reference implementation; and a fully documented, actionable methodology for evolutionary digitization of the healthcare industry. The project will address the key challenges of the healthcare ecosystem through prioritized delivery of applications and validation of business use cases, including but not be limited to end-to-end product tracking for combating counterfeit medicines and medical supplies; supply chain integrity; efficiency of recruitment and submission in clinical trials; and machine-learning health data marketplaces. The platform will support integrated use of medical devices across the use cases. The PharmaLedger project brings together 28 partners from 10 EU Member States, including 11 large pharmaceutical companies; highly innovative technology SMEs specializing in blockchain development, security, privacy and business intelligence; universities and research institutes specializing in pharmacoeconomic analysis, research of patient requirements, big data analytics and electronic health records; leading clinical trials companies; supply chain partners; patient representatives; and leading healthcare service providers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHARMALEDGER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PHARMALEDGER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

TRIC-TB (2019)

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Read More